Program
Gemcitabine
Also written as “gemcitabine”, “gemcitabine hydrochloride” and “AK112, Cadonilimab, nab-paclitaxel, gemcitabine”.
Its studies are mostly in Pancreatic Neoplasms · Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Neoplasms · Biliary Tract Neoplasms, led by 30 companies.
Drug pageGemcitabine: every studyMany companies study it; this page follows only the 128 they lead. All 1,376 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 681 open or running | phase 3since Nov 6, 2000 | Nov 6, 2000 | May 2027phase 2 · NCT05999994 |
| Hoffmann-La Rocheits history only | 181 open or running | phase 4since Mar 19, 2008 | Apr 17, 2007 | Mar 22, 2027phase 1 · NCT06624085 |
| Pfizerits history only | 50 open or running | phase 3since Jan 21, 2000 | Jan 21, 2000 | none ahead |
| GlaxoSmithKlineits history only | 40 open or running | phase 2since May 23, 2003 | May 23, 2003 | none ahead |
| Amgenits history only | 30 open or running | phase 2since Jul 5, 2000 | Jul 5, 2000 | none ahead |
| Astellas Pharmaits history only | 20 open or running | phase 1since Apr 9, 2002 | Apr 9, 2002 | none ahead |
| NovoCureits history only | 20 open or running | phase 2since Oct 23, 2013 | Oct 23, 2013 | none ahead |
| Pierre Fabreits history only | 20 open or running | phase 2since Apr 16, 2012 | Apr 16, 2012 | none ahead |
| Sarah Cannon Research Instituteits history only | 20 open or running | phase 2since Apr 4, 2008 | Apr 4, 2008 | none ahead |
| Theriva Biologics SLits history only | 20 open or running | phase 1since Jan 21, 2014 | Jan 21, 2014 | none ahead |
| Academic Thoracic Oncology Medical Investigators Consortiumits history only | 10 open or running | phase 2since Mar 24, 2016 | Mar 24, 2016 | none ahead |
| BeBetter Medits history only | 10 open or running | phase 2since Nov 11, 2024 | Nov 11, 2024 | none ahead |
| Betta Pharmaceuticalsits history only | 10 open or running | phase 4since Jul 16, 2014 | Jul 16, 2014 | none ahead |
| Coherus Oncologyits history only | 11 open or running | phase 4since Jun 10, 2024 | Jun 10, 2024 | Dec 2027phase 4 · NCT06457503 |
| EBG MedAustronits history only | 11 open or running | no phasesince May 10, 2021 | May 10, 2021 | Dec 31, 2026NCT04894643 |
| Eisaiits history only | 10 open or running | phase 2since May 17, 2010 | May 17, 2010 | none ahead |
| Hope Cancer Instituteits history only | 10 open or running | phase 2since Nov 1, 1999 | Nov 1, 1999 | none ahead |
| Jiangsu Healthy Life Innovation Medical Technologyits history only | 11 open or running | no phasesince Sep 20, 2024 | Sep 20, 2024 | none ahead |
| Meyer Pharmaceuticalsits history only | 10 open or running | phase 2since Nov 1, 1999 | Nov 1, 1999 | none ahead |
| Novaceaits history only | 10 open or running | phase 2since Sep 26, 2007 | Sep 26, 2007 | none ahead |
| Otsukaits history only | 10 open or running | phase 3since Jun 2, 2000 | Jun 2, 2000 | none ahead |
| Pharmacosmosits history only | 10 open or running | phase 2since Nov 18, 2016 | Nov 18, 2016 | none ahead |
| Pharmatech Oncologyits history only | 10 open or running | phase 2since Dec 7, 2001 | Dec 7, 2001 | none ahead |
| Relmada Therapeuticsits history only | 11 open or running | phase 2since Aug 8, 2024 | Aug 8, 2024 | Nov 2027phase 2 · NCT06663137 |
| RenovoRxits history only | 10 open or running | phase 1since Sep 8, 2014 | Sep 8, 2014 | none ahead |
| Shanghai Miracogenits history only | 11 open or running | phase 3since Feb 22, 2023 | Feb 22, 2023 | none ahead |
| Sino Biopharmaceuticalits history only | 10 open or running | phase 3since Jul 17, 2018 | Jul 17, 2018 | none ahead |
| Smartwise Sweden ABits history only | 11 open or running | phase 2since Apr 5, 2026 | Apr 5, 2026 | Dec 2027phase 2 · NCT07575191 |
| Swedish Orphan Biovitrumits history only | 10 open or running | phase 3since Feb 5, 2003 | Feb 5, 2003 | none ahead |
| SynerGene Therapeuticsits history only | 11 open or running | phase 2since Dec 18, 2014 | Dec 18, 2014 | Dec 2026phase 2 · NCT02340117 |
Also a collaborator on its studies: Ono Pharmaceutical, Baili-Bio (Chengdu) Pharmaceutical, AbbVie, Bristol-Myers Squibb, Criterium, AstraZeneca, PharmaBio Development, Johnson & Johnson, PPD DEVELOPMENT, LP, Merck, Sanofi and Prologue Research International.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Eli Lilly only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 7 studies since May 28, 2003.
- Sep 12, 200525 phase 2 studiesNCT00192101, NCT00192075, NCT00192062 and 22 more
- Sep 12, 20057 phase 3 studiesNCT00191646, NCT00191477, NCT00191438 and 4 more
- Apr 18, 20062 phase 2 studies in Breast NeoplasmsNCT00316199, NCT00320541
- May 15, 2006Phase 2 study in Pancreatic NeoplasmsNCT00326911 · 61 enrolled · United States
- Jun 6, 2006Phase 2 study in Breast NeoplasmsNCT00334802 · 62 enrolled · Japan
- Jul 24, 2006Phase 2 study in Lung NeoplasmsNCT00356525 · 41 enrolled · United States, Brazil, India
- Sep 22, 20062 phase 2 studiesNCT00380588, NCT00383331
- Jun 20, 20078 phase 2 studiesNCT00490399, NCT00489996, NCT00489983 and 5 more
- Feb 13, 2008Phase 2 study in Breast NeoplasmsNCT00623233 · 52 enrolled · United States
- Jul 8, 2010Phase 2 study in Carcinoma, Non-Small-Cell LungNCT01160744 · 280 enrolled · United States, Belgium, Canada and more
- May 24, 2012Phase 2 study in Carcinoma, Non-Small-Cell LungNCT01606748 · 35 enrolled · United States
- Oct 20, 2016Phase 2 study in Thoracic NeoplasmsNCT02941601 · United States, Belgium, Germany and more
- Dec 1, 2016Phase 2 study in Pancreatic NeoplasmsNCT02981342 · 106 enrolled · United States, Australia, Belgium and more
- Aug 14, 2023Phase 2 study in NeoplasmsNCT05999994 · 105 planned · United States, Australia, Belgium and more
Ahead
- May 2027Primary completion: phase 2 study in NeoplasmsNCT05999994
TargetBeta
“Ribonucleoside-diphosphate reductase RR1 inhibitor”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Hydroxyurearule | Norgine | phase 4 | 15 |
Studies
The newest 60 of 68 Eli Lilly leads. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05999994Neoplasms · United States, Australia, Belgium and more | 2 | Recruiting | May 2027 | 105 |
| NCT02981342Pancreatic Neoplasms · United States, Australia, Belgium and more | 2 | Completed | Apr 20, 2018 | 106 |
| NCT02941601Thoracic Neoplasms · United States, Belgium, Germany and more | 2 | Withdrawn | Dec 2017 | 0 |
| NCT01606748Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Jun 2013 | 35 |
| NCT01160744Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more | 2 | Completed | Jan 2014 | 280 |
| NCT00623233Breast Neoplasms · United States | 2 | Completed | Jan 2011 | 52 |
| NCT00491127Lymphoma, Non-Hodgkin · Spain | 2 | Completed | 10 | |
| NCT00491114Urinary Bladder Neoplasms · Italy | 2 | Completed | 8 | |
| NCT00490880Urinary Bladder Neoplasms · Poland | 2 | Completed | 2 | |
| NCT00490711Carcinoma, Ovarian Epithelial · Slovakia | 2 | Completed | 7 | |
| NCT00490659Carcinoma, Non-Small-Cell Lung · Poland | 2 | Completed | 13 | |
| NCT00490399Biliary Tract Carcinoma · Korea, Republic of | 2 | Completed | 39 | |
| NCT00489996Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | 100 | |
| NCT00489983Carcinoma, Non-Small-Cell Lung · Germany, Italy, United Kingdom | 2 | Completed | 91 | |
| NCT00383331Carcinoma, Non-Small-Cell Lung · United States | 2 | Terminated | Jan 2008 | 19 |
| NCT00380588Biliary Tract Neoplasms · Japan | 2 | Completed | Oct 2008 | 84 |
| NCT00356525Lung Neoplasms · United States, Brazil, India | 2 | Terminated | Jun 2008 | 41 |
| NCT00334802Breast Neoplasms · Japan | 2 | Completed | Feb 2008 | 62 |
| NCT00326911Pancreatic Neoplasms · United States | 2 | Terminated | Oct 2008 | 61 |
| NCT00320541Breast Neoplasms · United States, Puerto Rico | 2 | Completed | Apr 2009 | 187 |
| NCT00316199Breast Neoplasms · China | 2 | Completed | Apr 2008 | 60 |
| NCT00192101Breast Neoplasms · Saudi Arabia | 2 | Completed | 100 | |
| NCT00192075Colorectal Neoplasms · United States | 2 | Completed | 84 | |
| NCT00192062Breast Neoplasms · Egypt | 2 | Completed | 80 | |
| NCT00192049Non-Muscle Invasive Bladder Neoplasms · Israel | 2 | Completed | 90 | |
| NCT00192036Carcinoma, Non-Small-Cell Lung · Belgium | 2 | Completed | Jan 2008 | 49 |
| NCT00191971Urologic Neoplasms · Japan | 2 | Completed | 40 | |
| NCT00191841Carcinoma, Non-Small-Cell Lung · Russian Federation | 2 | Completed | 50 | |
| NCT00191815Breast Neoplasms · Germany, Russian Federation | 2 | Completed | 70 | |
| NCT00191789Breast Neoplasms · India | 2 | Completed | Apr 2009 | 65 |
| NCT00191763Carcinoma · Turkey | 2 | Completed | 52 | |
| NCT00191711Non-Muscle Invasive Bladder Neoplasms · Italy | 2 | Completed | 43 | |
| NCT00191672Breast Neoplasms · United States | 2 | Completed | 120 | |
| NCT00191646Genital Neoplasms, Female · United States, Puerto Rico | 3 | Completed | Aug 2009 | 919 |
| NCT00191620Carcinoma, Non-Small-Cell Lung · Argentina, Brazil, Chile and more | 2 | Completed | 64 | |
| NCT00191568Pancreatic Neoplasms · France | 2 | Completed | 45 | |
| NCT00191503Adenocarcinoma · Canada | 2 | Completed | 30 | |
| NCT00191490Carcinoma, Non-Small-Cell Lung · Italy | 2 | Completed | 162 | |
| NCT00191477Urinary Bladder Neoplasms · Germany | 3 | Terminated | Mar 2008 | 355 |
| NCT00191451Breast Neoplasms · United States | 2 | Completed | Oct 2008 | 150 |
| NCT00191438Breast Neoplasms · France, Germany, Italy and more | 3 | Completed | 300 | |
| NCT00191373Breast Neoplasms · United States | 2 | Completed | 66 | |
| NCT00191347Breast Neoplasms · Canada | 2 | Completed | 30 | |
| NCT00191334Ovarian Neoplasms · Russian Federation | 2 | Completed | Dec 2007 | 50 |
| NCT00191269Breast Neoplasms · Japan | 2 | Completed | Mar 2008 | 68 |
| NCT00191256Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | 77 | |
| NCT00191243Breast Neoplasms · Finland | 2 | Completed | Aug 2007 | 237 |
| NCT00191230Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | 70 | |
| NCT00191152Breast Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Nov 2008 | 475 |
| NCT00191139Carcinoma, Non-Small-Cell Lung · United States, Argentina, China and more | 2 | Completed | Nov 2008 | 64 |
| NCT00191126Carcinoma, Non-Small-Cell Lung · Belgium, Bosnia and Herzegovina, Bulgaria and more | 3 | Completed | Sep 2007 | 263 |
| NCT00191100Uterine Cervical Neoplasms · Argentina, Bosnia and Herzegovina, India and more | 3 | Completed | Apr 2008 | 515 |
| NCT00190710Carcinoma, Non-Small-Cell Lung · United States | 3 | Completed | 242 | |
| NCT00112346Carcinoma, Non-Small-Cell Lung · United States, Canada | 2 | Completed | Dec 2006 | 120 |
| NCT00101842Carcinoma, Transitional Cell · United States | 2 | Completed | 61 | |
| NCT00071136Lung Neoplasms · United States | 2 | Completed | 48 | |
| NCT00069875Carcinoma, Non-Small-Cell Lung · United States, Canada, Germany and more | 2 | Completed | 195 | |
| NCT00063570Breast Neoplasms · United States, Puerto Rico | 2 | Completed | Jan 2008 | 73 |
| NCT00061477Mesothelioma · United States | 2 | Completed | 48 | |
| NCT00061464Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | 48 |
How it is read
Names in the registry
- “Gemcitabine”, 113 entries
- “gemcitabine”, 52 entries
- “gemcitabine hydrochloride”, 17 entries
- “AK112, Cadonilimab, nab-paclitaxel, gemcitabine”, 3 entries
- “EndoTAG-1 and Gemcitabine”, 3 entries
Conditions, from the studies’ own filings
- Pancreatic Neoplasms, 53 studies
- Carcinoma, Non-Small-Cell Lung, 42 studies
- Breast Neoplasms, 24 studies
- Neoplasms, 10 studies
- Biliary Tract Neoplasms, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.